Asahi Kasei has started a Phase I clinical trial in Japan for AK1940, a peptide-based investigational compound for autoimmune diseases. The study will assess pharmacokinetics, safety and tolerability in healthy volunteers.
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
A redesigned CD40 agonist antibody achieved complete remission in two of 12 patients with metastatic cancer in early trials, while separate research identified a method to prevent deadly heart complications from immune checkpoint inhibitors.
Research shows TET2-driven clonal hematopoiesis improves immune checkpoint blockade efficacy in solid tumors, while separate studies identify new immune pathways in childhood brain cancers and mechanisms behind immunotherapy resistance.
